We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation Study of the Korean Version of the EORTC QLQ-HDC29

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01208532
Recruitment Status : Completed
First Posted : September 24, 2010
Last Update Posted : April 23, 2015
Sponsor:
Information provided by (Responsible Party):
Sung-Soo Yoon, Seoul National University Hospital

Brief Summary:
The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).

Condition or disease
Quality of Life After Stem Cell Transplantation

Study Type : Observational
Actual Enrollment : 226 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29
Study Start Date : September 2010
Primary Completion Date : December 2013
Study Completion Date : December 2013



Primary Outcome Measures :
  1. Reliability and validity of the Korean version of the EORTC HDC-29 [ Time Frame: at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT) ]

    Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency.

    Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who are diagnosed with hematologic malignancies and who are planned to recieve high-dose chemotherapy followed by allo or auto stem cell transplantation in Seoul National University Hospital, Korea
Criteria

Inclusion Criteria:

  • Patients who are aged more than 18 years
  • Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT)
  • Patients who agree with the informed consent

Exclusion Criteria:

  • Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01208532


Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Principal Investigator: Sung-Soo Yoon, MD, PhD Seoul National University Hospital
Principal Investigator: Jung Mi Oh, Pharm.D. College of Pharmacy, Seoul National University